CMMB news · CMMB stock

SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study

Yahoo Finance · Oct 22, 2025 · Chemomab Therapeutics Ltd DRC (CMMB)

Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.